ArticleJCO precision oncology2024

Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2.

Erica S Tsang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.